154 related articles for article (PubMed ID: 25180623)
21. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
Khanna R; Smith MJ
Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
[TBL] [Abstract][Full Text] [Related]
22. Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study.
Roodenrijs NMT; Welsing PMJ; van der Goes MC; Tekstra J; Lafeber FPJG; Jacobs JWG; van Laar JM
Rheumatology (Oxford); 2021 Oct; 60(10):4681-4690. PubMed ID: 33502493
[TBL] [Abstract][Full Text] [Related]
23. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
24. A multicenter cost-of-illness study on rheumatoid arthritis in Italy.
Leardini G; Salaffi F; Montanelli R; Gerzeli S; Canesi B
Clin Exp Rheumatol; 2002; 20(4):505-15. PubMed ID: 12175106
[TBL] [Abstract][Full Text] [Related]
25. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis.
Furneri G; Mantovani LG; Belisari A; Mosca M; Cristiani M; Bellelli S; Cortesi PA; Turchetti G
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S72-84. PubMed ID: 23072761
[TBL] [Abstract][Full Text] [Related]
26. Heart rate variability testing: could it change spending for rheumatoid arthritis patients in the United States? An exploratory economic analysis.
Zimmermann M; Vodicka E; Holman AJ; Garrison LP
J Med Econ; 2018 Jul; 21(7):712-720. PubMed ID: 29701508
[TBL] [Abstract][Full Text] [Related]
27. Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents.
Ohinmaa AE; Thanh NX; Barnabe C; Martin L; Russell AS; Barr SG; Maksymowych WP
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1319-27. PubMed ID: 24470178
[TBL] [Abstract][Full Text] [Related]
28. Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study.
Tanaka E; Inoue E; Mannalithara A; Bennett M; Kamitsuji S; Taniguchi A; Momohara S; Hara M; Singh G; Yamanaka H
Mod Rheumatol; 2010 Feb; 20(1):46-53. PubMed ID: 19821162
[TBL] [Abstract][Full Text] [Related]
29. An economic approach to health care.
Homik JE; Suarez-Almazor M
Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):203-18. PubMed ID: 15121040
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
[TBL] [Abstract][Full Text] [Related]
31. Review of health economics modelling in rheumatoid arthritis.
Emery P
Pharmacoeconomics; 2004; 22(2 Suppl 1):55-69. PubMed ID: 15157004
[TBL] [Abstract][Full Text] [Related]
32. The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis.
Silverman S; Dukes EM; Johnston SS; Brandenburg NA; Sadosky A; Huse DM
Curr Med Res Opin; 2009 Apr; 25(4):829-40. PubMed ID: 19220165
[TBL] [Abstract][Full Text] [Related]
33. Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis.
Vanderpoel J; Tkacz J; Brady BL; Ellis L
Clin Ther; 2019 Jun; 41(6):1080-1089.e5. PubMed ID: 31122662
[TBL] [Abstract][Full Text] [Related]
34. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
35. Impact of managed care on the use of biologic agents for rheumatoid arthritis.
Yelin EH; Trupin LS; Katz PP
Arthritis Rheum; 2005 Jun; 53(3):423-30. PubMed ID: 15934109
[TBL] [Abstract][Full Text] [Related]
36. The underestimated long term medical and economic consequences of rheumatoid arthritis.
Pincus T
Drugs; 1995; 50 Suppl 1():1-14. PubMed ID: 8714794
[TBL] [Abstract][Full Text] [Related]
37. Rheumatoid arthritis: direct and indirect costs.
Rat AC; Boissier MC
Joint Bone Spine; 2004 Nov; 71(6):518-24. PubMed ID: 15589432
[TBL] [Abstract][Full Text] [Related]
38. The costs of rheumatoid arthritis.
Allaire SH; Prashker MJ; Meenan RF
Pharmacoeconomics; 1994 Dec; 6(6):513-22. PubMed ID: 10155281
[TBL] [Abstract][Full Text] [Related]
39. Extra-articular Manifestations and Comorbidity in Rheumatoid Arthritis: Potential Impact of Pre-Rheumatoid Arthritis Prevention.
Giles JT
Clin Ther; 2019 Jul; 41(7):1246-1255. PubMed ID: 31196641
[TBL] [Abstract][Full Text] [Related]
40. The costs of rheumatoid arthritis: an international long-term view.
Pugner KM; Scott DI; Holmes JW; Hieke K
Semin Arthritis Rheum; 2000 Apr; 29(5):305-20. PubMed ID: 10805355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
